The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism

Detalhes bibliográficos
Autor(a) principal: Banerjee, Yajnavalka
Data de Publicação: 2021
Outros Autores: Stoian, Anca Pantea, Silva-Nunes, José, Sonmez, Alper, Rizvi, Ali A., Janez, Andrej, Rizzo, Manfredi
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.21/13684
Resumo: Introduction: A number of anti-diabetic treatments have been favored during the continuing spread of the current SARS-CoV-2 pandemic. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are a group of antidiabetic drugs, the glucose-reducing effect of which is founded on augmenting glucose-dependent insulin secretion with concomitant reduction of glucagon secretion and delayed gastric emptying. Apart from their glucose-lowering effects, GLP1-RAs also exert a plethora of pleiotropic activities in the form of anti-inflammatory, anti-thrombotic, and anti-obesogenic properties, with beneficial cardiovascular and renal impact. All these make this class of drugs a preferred option for managing patients with type 2 diabetes (T2D), and potentially helpful in those with SARS-CoV2 infection. Areas covered: In the present article we propose a hypothetical molecular mechanism by which GLP1-RAs may interact with SARS-CoV-2 activity. Expert opinion: The beneficial properties of GLP1-RAs may be of specific importance during COVID-19 infection for the most fragile patients with chronic comorbid conditions such as T2D, and those at higher cardiovascular and renal disease risk. Yet, further studies are needed to confirm our hypothesis and preliminary findings available in the literature.
id RCAP_b4a277cd67130580e549fb55944eb26c
oai_identifier_str oai:repositorio.ipl.pt:10400.21/13684
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanismCOVID-19SARS-CoV-2GLP-1RACoronavirusDiabetesPandemicIntroduction: A number of anti-diabetic treatments have been favored during the continuing spread of the current SARS-CoV-2 pandemic. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are a group of antidiabetic drugs, the glucose-reducing effect of which is founded on augmenting glucose-dependent insulin secretion with concomitant reduction of glucagon secretion and delayed gastric emptying. Apart from their glucose-lowering effects, GLP1-RAs also exert a plethora of pleiotropic activities in the form of anti-inflammatory, anti-thrombotic, and anti-obesogenic properties, with beneficial cardiovascular and renal impact. All these make this class of drugs a preferred option for managing patients with type 2 diabetes (T2D), and potentially helpful in those with SARS-CoV2 infection. Areas covered: In the present article we propose a hypothetical molecular mechanism by which GLP1-RAs may interact with SARS-CoV-2 activity. Expert opinion: The beneficial properties of GLP1-RAs may be of specific importance during COVID-19 infection for the most fragile patients with chronic comorbid conditions such as T2D, and those at higher cardiovascular and renal disease risk. Yet, further studies are needed to confirm our hypothesis and preliminary findings available in the literature.Taylor & FrancisRCIPLBanerjee, YajnavalkaStoian, Anca PanteaSilva-Nunes, JoséSonmez, AlperRizvi, Ali A.Janez, AndrejRizzo, Manfredi2021-09-06T10:06:22Z2021-112021-11-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.21/13684engBanerjee Y, Stoian AP, Silva-Nunes J, Sonmez A, Rizvi AA, Janez A, et al. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021;20(11):1309-15.10.1080/14740338.2021.1970744info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-03T10:08:48Zoai:repositorio.ipl.pt:10400.21/13684Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:21:35.011994Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism
title The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism
spellingShingle The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism
Banerjee, Yajnavalka
COVID-19
SARS-CoV-2
GLP-1RA
Coronavirus
Diabetes
Pandemic
title_short The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism
title_full The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism
title_fullStr The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism
title_full_unstemmed The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism
title_sort The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism
author Banerjee, Yajnavalka
author_facet Banerjee, Yajnavalka
Stoian, Anca Pantea
Silva-Nunes, José
Sonmez, Alper
Rizvi, Ali A.
Janez, Andrej
Rizzo, Manfredi
author_role author
author2 Stoian, Anca Pantea
Silva-Nunes, José
Sonmez, Alper
Rizvi, Ali A.
Janez, Andrej
Rizzo, Manfredi
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv RCIPL
dc.contributor.author.fl_str_mv Banerjee, Yajnavalka
Stoian, Anca Pantea
Silva-Nunes, José
Sonmez, Alper
Rizvi, Ali A.
Janez, Andrej
Rizzo, Manfredi
dc.subject.por.fl_str_mv COVID-19
SARS-CoV-2
GLP-1RA
Coronavirus
Diabetes
Pandemic
topic COVID-19
SARS-CoV-2
GLP-1RA
Coronavirus
Diabetes
Pandemic
description Introduction: A number of anti-diabetic treatments have been favored during the continuing spread of the current SARS-CoV-2 pandemic. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are a group of antidiabetic drugs, the glucose-reducing effect of which is founded on augmenting glucose-dependent insulin secretion with concomitant reduction of glucagon secretion and delayed gastric emptying. Apart from their glucose-lowering effects, GLP1-RAs also exert a plethora of pleiotropic activities in the form of anti-inflammatory, anti-thrombotic, and anti-obesogenic properties, with beneficial cardiovascular and renal impact. All these make this class of drugs a preferred option for managing patients with type 2 diabetes (T2D), and potentially helpful in those with SARS-CoV2 infection. Areas covered: In the present article we propose a hypothetical molecular mechanism by which GLP1-RAs may interact with SARS-CoV-2 activity. Expert opinion: The beneficial properties of GLP1-RAs may be of specific importance during COVID-19 infection for the most fragile patients with chronic comorbid conditions such as T2D, and those at higher cardiovascular and renal disease risk. Yet, further studies are needed to confirm our hypothesis and preliminary findings available in the literature.
publishDate 2021
dc.date.none.fl_str_mv 2021-09-06T10:06:22Z
2021-11
2021-11-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.21/13684
url http://hdl.handle.net/10400.21/13684
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Banerjee Y, Stoian AP, Silva-Nunes J, Sonmez A, Rizvi AA, Janez A, et al. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021;20(11):1309-15.
10.1080/14740338.2021.1970744
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133487148564480